Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
Open accessThe DOI matches its Crossref record; 121 of the 122 references it cites were found in a registry or an index.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for steatotic liver disease associated with metabolic syndrome. MASLD is the most common cause of chronic liver disease and is the leading cause of liver-related morbidity and mortality. It is important that all stakeholders be involved in tackling the public health threat of obesity and obesity-related diseases, including MASLD. A simple and clear assessment and referral pathway using non-invasive tests is essential to ensure that patients with severe MASLD are identified and referred to specialist care, while patients with less severe disease remain in primary care, where they are best managed. While lifestyle intervention is the cornerstone of the management of patients with MASLD, cardiovascular disease risk must be properly assessed and managed because cardiovascular disease is the leading cause of mortality. No pharmacological agent has been approved for the treatment of MASLD, but novel anti-hyperglycemic drugs appear to have benefit. Medications used for the treatment of diabetes and other metabolic conditions may need to be adjusted as liver disease progresses to cirrhosis, especially decompensated cirrhosis. Based on non-invasive tests, the concepts of compensated advanced chronic liver disease and clinically significant portal hypertension provide a practical approach to stratifying patients according to the risk of liver-related complications and can help manage such patients. Finally, prevention and management of sarcopenia should be considered in the management of patients with MASLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The growing yearly prevalence of Metabolic Dysfunction–non-alcoholic fatty liver disease (MASLD) has emerged as a worldwide public health concern, driven by improved living conditions, evolving lifestyle habits, and the widespread occurrence of obesity, diabetes, and metabolic syndrome.1”
From The Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis of Randomized Controlled Trials with Subgroup Analysis by Diabetes Status (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This is because the clinical definition of MASLD, as previously noted, includes not only the presence of steatosis but also a cardiometabolic context [31,32,33], which cannot be fully reproduced in a monoculture of hepatocyte-like cells.”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818 · cited 2×
“102 Of late, there is a growing interest in studies on the association between sarcopenia and MASLD.”
BackgroundEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citationWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000066 · Cited by 4,347
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Cited by
Items 701–784 of 784
Chen, L., Xu, Y., Zhang, J., & Lu, P. (2026) · Nutrition Journal · doi:10.1186/s12937-026-01366-y
Violet, P.-C., Greene, T., Teng, S., Wang, Y., Leonard, S. W., Head, B., Wright, E. C., Shamburek, R. D., Traber, M. G., Levine, M., et al. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101717
Mahalpure, S., Mahalpure, G. S., Daga, V., & Nehete, H. (2026) · Journal of Pharmaceutical and Biopharmaceutical Research · doi:10.25082/jpbr.2026.01.002
Editorial for “High‐Throughput Quantitative Chemical Shift‐Encoded MRI of the Liver”
Kafali, S. G. (2026) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.70450
Liu, X., & Zhou, C. (2026) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/cjgh/4834539
Zeng, J., Liang, J. B., Zhang, H., Wang, H. J., 林, 哲., Zhang, W., Zhang, H., Deng, X., Lin, J., Liu, M., et al. (2026) · Hepatology Research · doi:10.1111/hepr.70238
Romeo, M., Nardo, F. D., Basile, C., Napolitano, C., Vaia, P., Puorto, L. D., Indipendente, M., Gregorio, A. D., Dallio, M., & Federico, A. (2026) · Livers · doi:10.3390/livers6040071
Chen, F., Guan, Y., Liu, N., & Jing, W. (2026) · Comprehensive physiology · doi:10.1002/cph4.70218
Tacke, F., Kim, Y., Haas, J. S., Daumont, M., Maas, C., O’Donnell, J., & Schattenberg, J. M. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2026-0092
Obesity phenotypes, omics signatures, and risk of adverse liver outcomes
Zhao, L., Chen, Y., Li, J., Wang, C., Taddei, T. H., Ma, X., Ma, S., Demler, O., Yazdani, A., Osifala, O., et al. (2026) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djag242
Quinoa regulates hepatic lipid metabolism in MASLD mice via PPARγ-PLIN2
Liu, P., Wan, J., Qiao, L., Zhang, W., Sun, B., Hu, M., Zhang, Y., Jing, X., Wang, Y., Hu, Y., et al. (2026) · Food & Function · doi:10.1039/d6fo00954a
Mohammed, E. S. I., Shawky, M., ALMatrafi, T. A., Mathew, R. T., Ashour, M., Albaloushi, M. T. S., Almohaimeed, H. M., Eissa, E. H., & Abdelnour, S. A. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103812
Shi, Y., Han, Y., Zhang, H., Zhang, Y., Wei, W., Xu, W., Bao, X., & Lu, C. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158653
Understanding regional differences in MASLD: the Indian perspective
Harini, K. S., & Ezhilarasan, D. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00123-3
Ding, J., Liu, T., Huang, P., Yang, L., Chen, Z., Xue, Y., Hua, Y., Song, H., & Zheng, P. (2026) · Pharmaceuticals · doi:10.3390/ph19081195
Tatoli, R., Donghia, R., Carella, N., Cerabino, N., Chito, M. D., Zappimbulso, M., Pesole, P. L., Stabile, D., Ferro, A., Pascale, G., et al. (2026) · Nutrients · doi:10.3390/nu18152476
Rahim, H., Salih, N. A., & Azhdar, B. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103694
Ng, X., Teh, J., Sthaneshwar, P., Badaruddin, I. A., Puspanathan, P., Mustapha, N. R. N., Mahadeva, S., & Chan, W. (2026) · JGH Open · doi:10.1002/jgh3.70455
Self-citationAbenavoli, L., Scarlata, G. G. M., Gambardella, M. L., Loricchio, A. G., Giovanni, F. D., & Bendriss, G. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102131
Ehtiati, S., Hatami, B., Khatami, S. H., Ahmadzade, R., Zarei, T., Sirati‐Sabet, M., Abdi, S., Hajimohammadebrahim‐Ketabforoush, M., Namvarjah, F., Boostanipour, A., et al. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117214
Naghshtabrizi, B., Ataei, E., Naserian, S., Bagheri, L., & Ghobakhlou, M. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-05184-8
Li, R., Yang, Z., Chen, Y., Li, Y., Xu, H., & Rao, Z. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02242-9
Cardiometabolic Syndrome Part 1: Epidemiology, Pathophysiology, and Prevention Strategies
Lim, S. K., Hwang, Y., Son, J. W., Lee, S., Jung, C. H., Kim, H., Lim, H., Jo, S., Ihm, S., Sohn, I. S., et al. (2026) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2026.6.e25
Vitamin D and Metabolic Syndrome: Molecular Mechanisms and Clinical Implications: A Narrative Review
Fuentes-Barría, H., Aguilera-Eguía, R. A., Alarcón-Rivera, M., & Flores-Fernández, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167101
Liu, Y., Ju, L., Shi, L., Wei, L., Wang, J., Shen, Z., Chen, L., Shao, J., Mao, L., & Bian, Z. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06379-8
The Six Pillars of Lifestyle Medicine in MASLD : An Evidence‐Based Guide
Sharma, J., & Viveiros, K. (2026) · Liver international communications. · doi:10.1002/lci2.70054
The menopause-obesity axis in MASH progression: from estrogen decline to liver fibrosis
Ntikoudi, A., & Vlachou, E. D. (2026) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2026.1889458
Meng, Q., Wang, X., Zhang, Y., Pushpakom, S. P., Yang, J., Feng, H., & Wang, M. (2026) · PLoS ONE · doi:10.1371/journal.pone.0354751
Xu, W., Liu, L., Sun, M., Zhang, R., Chen, J., & Shen, Y. (2026) · Viruses · doi:10.3390/v18080896 · Cited by 1
Mohamed, D. A., Mabrok, H. B., A.Bassuoni, R., & Hamed, I. M. (2026) · Food & Function · doi:10.1039/d6fo02410f
El-Messallamy, F. A. F., Mousa, M. M., Soliman, A. S., El-Dosoky, O. I., Hussein, S., Elsayed, B. S., & Osama, S. M. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00697-w
Cliff, K. L., Guanzon, D., Lai, A., Scholz‐Romero, K., Christiansen, G., Handberg, A., Salomón, C., & Mellergaard, M. (2026) · Journal of Extracellular Biology · doi:10.1002/jex2.70173 · Cited by 1
Casimo, G., Donghia, R., Bonfiglio, C., Tatoli, R., Biancofiore, G. M., & Giannelli, G. (2026) · Biomedicines · doi:10.3390/biomedicines14081860
da Silva, D. L. B., Gouveia, J. F., de Oliveira, B. C., Cavalheira, M. A., Nogueira, N. P. D. A., Paes, M. C., da Silva, S. V., Nascimento, A. L. R., de Carvalho, J. J., Ognibene, D. T., et al. (2026) · Molecules · doi:10.3390/molecules31162925
Fu, Y., Lin, Y., Liu, F., Qiu, J., Chen, L., Dou, X., & Liang, X. H. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c16995
Yun, E.-K., Ahn, S.-H., Song, Y.-H., Jung, W.-R., Jeon, S.-Y., Lee, H.-S., Son, D., & Lee, Y. (2026) · Lipids in Health and Disease · doi:10.21203/rs.3.rs-10672212/v1
Kresevic, S., Giuffrè, M., Bortolotto, A., Bonazza, D., Giacomello, E., Miladinović, A., Casagranda, B., Palmisano, S., Crocè, L. S., & Ajčević, M. (2026) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2026.111904
Rapizzi, E., Zanatta, L., Guarnieri, G., Martinelli, S., Comeglio, P., Acciai, G., Tavanti, M., Filippi, S., Canu, L., Morelli, A., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03033-9
Cell-specific cPGES control of glucocorticoid receptor function drives MASLD progression
Zhong, D., Qiao, R., Quan, G., Song, C., Fu, K., Zou, Y., Qi, X., Su, W., Liu, Y., Li, F., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117901 · Cited by 1
Lee, Y. S., Jeong, C.-Y., Chung, Y. W., Lee, Y., Lee, D. H., Bang, J. Y., Kim, D. Y., Lee, H., Oh, S., Bhin, J., et al. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01811-2
Yu, Q., Wang, R., Xie, Y., Liu, X., Ma, W., Liu, Q., & Li, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177794
The monoacylglycerol acyltransferase 2 inhibitor VB-85387 reduces MASLD
Gallo-Ebert, C., Wayne, J., Brown, A., & Nickels, J. T. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101137
Alswat, K., Sanai, F., Alansare, A. B., Abdellatif, A., Elbadry, M., Zaky, S., Ibrahim, M., Hagag, M., Alhussain, M., Asswini, S. A., et al. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-05306-2
卢, 晨. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1693076
Lee, S., Song, Y., Kim, S., Leprat, Q., Choi, I., Kim, J.-H., Lee, Y.-J., & Seo, H. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158772
Zhao, C., Gao, Y., Zhou, T., Sun, L., & Qu, Q. (2026) · Pharmaceuticals · doi:10.3390/ph19091402
Vitamin E treatment modulates steatotic and attenuates oxidative stress in a MASLD in vitro model
Teymoorian, S. K., Nouri, K., Choshali, M. A., Hassan, M., Rismani, E., Vosough, M., & Piryaei, A. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12691-0
Burzyńska, M., & Pikala, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187001
Riahy, S., Hamidian, G., Al-Ziyadi, H. H., & Hamedchaman, N. (2026) · Hepatitis Monthly · doi:10.5812/hepatmon-169226
Xu, G., Pan, T., Wang, G., Qiu, F., Leng, J., Feng, Q., Xue, Y., Wang, Y., Zheng, J., Lu, H., et al. (2026) · MedComm · doi:10.1002/mco2.70999
Wang, C.-X., Kang, J., Zhang, J., Yuan, X.-Y., Wang, D., Li, M.-Q., & Liu, D.-F. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-05290-7
Ferroptosis in metabolic dysfunction-associated steatotic liver disease
Kotlyarov, S. N., Iskrina, A., & Котлярова, А. А. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1912709
FAPi‐Mediated siRNA Lipid Nanoparticles for the Treatment of Liver Fibrosis
冯如兰, Zhu, S., Yao, Z., Li, J., Feng, Y., Zhou, Z., Wang, J., Lu, W., Liu, Y., Zhan, C., et al. (2026) · Small · doi:10.1002/smll.75839
Cardiovascular–kidney–metabolic syndrome as a mitochondrial systems disorder
Shen, L., Abel, E. D., Arany, Z. P., Baur, J. A., Pei, L., & Suszták, K. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01127-4 · Cited by 1
Abdel-Mageed, M., Shamaa, M. M., Labane, M., Elmansoury, N., & Wahid, A. M. (2026) · Scientific Reports · doi:10.1038/s41598-026-67040-9
Classification-Guided Multi-Organ Segmentation in Abdominal Ultrasound via Feature Injection
Kresevic, S., Bortolotto, A., Giuffrè, M., Fusaro, L., Gulotta, M., Sartori, M., Orbosuè, F., Miladinović, A., Crocè, L. S., & Ajčević, M. (2026) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-032-37739-5_5
Kotlyarov, S. N., Котлярова, А. А., Catanzaro, R., & Marotta, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198614
Jang, S. J., & Shine, B.-K. (2026) · Daehan imsang geon-gang jeungjin hakoeji/Daehan imsang geon'gang jeungjin haghoeji · doi:10.15384/kjhp.2026.00283
Ghorbani, Y., Schwenger, K. J. P., Maughan, H., Teterina, A. A., Lou, W., Comelli, E. M., Fischer, S. E., Jackson, T. D., Okrainec, A., & Allard, J. P. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106498
Goswami, P., Ray, S. K., Singhai, A., & Mukherjee, S. (2026) · Journal of the National Medical Association · doi:10.1016/j.jnma.2026.09.007
Dempster, N. J., Gade, F. S., Daly, C., Mbasu, R. J., Chen, L., Dong, J., Gangitano, E., Sgromo, B., Gillies, R. S., White, S. J., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156793
Haque, M., Lesker, T. R., Rolle-Kampczyk, U. E., Segers, A., de Vos, W. M., Molinaro, A., Raju, T. B., Chen, Y., Backhaus, M., Mohamed, M. R., et al. (2026) · Gut · doi:10.1136/gutjnl-2026-338178
Zhang, C., Yan, J., Liu, R., & Qiu, C. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1887276
Guo, T., Zhao, Y., Wang, S., Shen, C., & Jiang, Q. (2026) · medRxiv · doi:10.64898/2026.10.06.26364867
Pandey, A., Badruddeen, B., Akhtar, J., Khan, M. I., Ahmad, M., & Islam, A. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179400
Li, S., Yang, Z., Huang, X., 仲明惟, Lin, S., Liu, T., Zhao, H., 刘少壮, Zhao, S., & Chen, Z.-J. (2026) · Hepatology International · doi:10.1007/s12072-026-11159-4
Juárez-Hernández, E., Bautista-Mondragón, C. A., López-Pérez-Alférez, A., Castro‐Narro, G., & López-Méndez, I. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102153
Almutairi, S. O., Yagoub, A. E. A., & Barakat, H. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1982241
Reytor-González, C., Román-Galeano, N. M., Gavilanes, D. J., Rossetti, G., Cobellis, L., Pilone, V., Simancas‐Racines, D., & Schiavo, L. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100348
Tatoli, R., Donghia, R., Pesole, P. L., Chito, M. D., Stabile, D., Ferro, A., Ancona, A., Casimo, G., & Giannelli, G. (2026) · Nutrients · doi:10.3390/nu18203397
Go, Y.-H., Lee, S.-R., Kim, J.-H., Han, S., Choi, J., Lee, K.-Y., Ahn, H., Kwon, S., Kim, B., han, K., et al. (2026) · Heart Rhythm · doi:10.1016/j.hrthm.2026.10.016
Effect of uric acid and estimated glomerular filtration rate on the Fibrosis-4 index
Xu, W., Chen, D., Lou, S., Wu, J., Liu, Y., Liu, R., & Chen, H. (2026) · Medicine · doi:10.1097/md.0000000000051217
Eusuff, S., Kim, J., Fatima, Z., Yalcinkaya, D., Sahashi, Y., Sandhu, A., Nguyen, L. H., Ambrosy, A. P., Cheng, P. P., Chang, S. T., et al. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107628
Fatty liver disease: contribution of the introduction of new nomenclature into clinical practice
Aliyev, S., Hidayatov, A., & Aliyev, E. (2026) · Clinical Medicine (Russian Journal) · doi:10.30629/0023-2149-2026-104-7-513-520
Kumari, D., Chaudhary, A., Kaushik, V., Sharma, A., Sasibhushan, V., Dikshit, M., & Kumar, A. (2026) · PharmaNutrition · doi:10.1016/j.phanu.2026.100548
de Araujo, B. P., Silvares, R. R., Pereira, E. N. G. D. S., Rodrigues, K. L., van de Waarenburg, M. P. H., Scheijen, J. L. J. M., Fernandes‐Santos, C., Wouters, K., Schalkwijk, C. G., & Daliry, A. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.120013
Ji, H., Pan, R., & Huang, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1987830
Empagliflozin’s role in cardiometabolic disease treatment: an Egyptian expert’s view
Khalil, S. H. A., Elmessallamy, F., Elhadidy, K. E., Hefnawy, M. H. M. F. E., Halawa, M. R., Zeitoun, M., Hussein, S., & Elebrashy, I. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02312-y
Wu, M., & Li, N. (2026) · Central European Journal of Immunology · doi:10.5114/ceji/231247
The role of ferroptosis in diabetes and its multiple complications
Qi, Y., Zhang, M., Sun, F., Li, H., Liu, J., Zhang, Z., Wang, W., & Yang, Y. (2026) · Medicine Plus · doi:10.1016/j.medp.2026.100177
Alkaline phosphatase refines FIB-4–based prediction of liver outcomes and mortality in MASLD
Shimoni, O., Hajaj, E., Kushnir, S., & Shlomai, A. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.10.026
Lee, G. B., Han, B., Kim, Y., Jung, S. P., Cho, K. R., & Song, S. E. (2026) · Journal of Breast Cancer · doi:10.4048/jbc.2026.0077
Pore, S., & Roy, K. (2026) · ACS ES&T Toxicology · doi:10.1021/acsesttox.6c00050
Metadata
- Authors
- Chan, W.-K., Chuah, K.-H., Rajaram, R. B., Lim, L.-L., Ratnasingam, J., & Vethakkan, S. R.
- Affiliations
- University of Malaya (MY)
- Chinese University of Hong Kong (HK)
- Corresponding author
- Chan, Wah-Kheong
- Venue
- Journal of Obesity & Metabolic Syndrome
- Published
- 2023-09-13
- Volume
- 32
- Issue
- 3
- Pages
- 197-213
- ISSN
- 2508-6235 (ISSN-L)
- 2508-7576
- PMC
- PMC10583766
- OpenAlex
- W4386704735
- Cited by
- 776
- References
- 122
- Citations by year
- 2026: 245 · 2025: 342 · 2024: 183 · 2023: 5
- FWCI
- 30.29
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Journal of Obesity & Metabolic Syndrome (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, metabolic syndrome, obesity, chronic liver disease, non-invasive liver assessment, referral pathways, lifestyle intervention, cardiovascular risk, anti-hyperglycemic drugs, liver cirrhosis, decompensated cirrhosis, compensated advanced chronic liver disease, clinically significant portal hypertension, sarcopenia, liver complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.